scholarly journals Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 325
Author(s):  
Maciej Majcherek ◽  
Agnieszka Matkowska-Kocjan ◽  
Donata Szymczak ◽  
Magdalena Karasek ◽  
Agnieszka Szeremet ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Count ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Univariate Analysis ◽  
Humoral Response ◽  
Hematopoietic Stem

Vaccination against SARS-CoV-2 is currently the best tool in the fight against the COVID-19 pandemic. However, there are limited data on its efficacy and safety after hematopoietic stem cell transplantation (HCT). We present the results of a prospective analysis of the humoral response to two doses of BNT162b2 mRNA vaccine in 93 adult patients, including 29 after autologous HCT (autoHCT) and 64 after allogeneic HCT (alloHCT). Positive anti-SARS-CoV-2 antibodies were detected before vaccination in 25% of patients despite a negative medical history of COVID-19. Seroconversion after vaccination was achieved in 89% of patients after alloHCT and in 96% after autoHCT, without grade 3/4 adverse events. Post-vaccination anti-SARS-CoV-2 antibody level correlated with the time from transplant and absolute B-cell count at the vaccination. In univariate analysis restricted to the alloHCT group, short time since transplantation, low B-cell count, low intensity conditioning, GvHD, and immunosuppressive treatment at the vaccination were associated with lack of seroconversion. In the multivariate model, the only negative predictor of seroconversion remained treatment with calcineurin inhibitor (CNI). In conclusion, the BNT162b2 mRNA vaccine is highly immunogenic in patients after HCT, but treatment with CNI at the time of vaccination has a strong negative impact on the humoral response

Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation

2015 ◽  
Vol 95 (6) ◽  
pp. 514-523 ◽  
Author(s):  
Petra Roll ◽  
Khalid Muhammad ◽  
Gernot Stuhler ◽  
Ulrich Grigoleit ◽  
Hermann Einsele ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem

scholarly journals RECONSTITUTION OF B-CELLS IMMUNITY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

2020 ◽  
Vol 19 (2) ◽  
pp. 22-30
Author(s):  
S. V. Chulkova ◽  
N. N. Subbotina ◽  
G. D. Petrova ◽  
N. V. Sidorova ◽  
O. P. Kolbatskaya ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
B Lymphopoiesis ◽  
Hematopoietic Stem ◽  
Cell Immunity ◽  
B Cell Immunity

The restoration of B-cell immunity is a key component of the success of allogeneic hematopoietic stem cell transplantation. In most cases, the restoration of B-lymphopoiesis is a slow and often incomplete process, which is accompanied by a decrease in the tolerance of the recipient to bacterial, viral, fungal pathogens. This process is influenced by a number of factors that determine its effectiveness and pace. It is important to restore not only the size of the B-cell population, but also their functional usefulness. The article provides an analysis of modern literature data on the significance of the restoration of B-cell immunity after allogeneic hematopoietic stem cell transplantation, a review of the main factors affecting the process of B-lymphopoiesis, and their prognostic component.

scholarly journals Modified Beac Conditioning Regimen with Idarubicin Followed By Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective for Invasive B-Cell Non-Hodgkin's Lymphoma Patients

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 7-7
Author(s):  
Chen Tian
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Hematopoietic Stem ◽  
Non Hodgkin's Lymphoma

High-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory (R/R) B-cell Non-Hodgkin's lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC). We compared the outcomes of 72 B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn't occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group were a little longer than that of BEAC group. 2-year OS and PFS rate were higher in IEAC group compared to BEAC group. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase (LDH) level, remission of disease, modified regimen were related with the prognosis. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could effectively prolong the survival of patients. Disclosures No relevant conflicts of interest to declare.

Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2745-2745
Author(s):  
Paul Harker-Murray ◽  
Jakub Tolar ◽  
Ye Tan ◽  
Margaret L. MacMillan ◽  
John Wagner ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Pediatric Patients ◽  
Hematopoietic Stem ◽  
Cns Relapse

Abstract Treatment options for pediatric patients with isolated central nervous system (CNS) relapse of acute lymphoblastic leukemia (ALL) include intensive chemotherapy followed by craniospinal irradiation and hematopoietic stem cell transplantation (HSCT). However, there is little information regarding outcomes of HSCT in this situation. At the University of Minnesota 15 patients <18 years of age underwent allogeneic HSCT for ALL with isolated CNS relapses between 1990 and 2004. Leukemic subtypes included B cell (7), pre-B cell (6), T cell (1), and ALL NOS (1). All patients were in remission at the time of transplantation; 9 patients were in CR2, 5 patients were in CR3, and 1 patient was in CR5. Median duration of CR1 in all patients was 21.9 months (range 8.5–57.7) with median time from diagnosis of ALL to CNS relapse 23.4 months (range 8.9–127.7) in all patients. For patients transplanted in CR2, the median duration of 1st CR was 16.2 months (range 8.5–30.1). For all patients, transplantation was performed following a relapse limited to the CNS. Stem cell sources were related in 8 cases (5 HLA-matched marrow, 2 mismatched marrow, 1 matched cord blood) and unrelated in 7 (3 mismatched URD marrow, 2 5/6 matched cord blood, 2 4/6 matched cord blood). Preparative regimens included total body irradiation (TBI) and cyclophosphamide (Cy) for 12 patients, and Cy, TBI, VP16 for 3 patients. Grade II-IV GvHD occurred in 7 patients (47%; 95% CI 21–72) and grade III-IV in 3 patients (20%; 95% CI 0–40) by day 100. All patients were alive 1 year following transplantation. With a median follow-up of 7 years (range 1 to 19.4), the estimated 5 year survival is 78% (95% CI 51–100%). Of the 2 patients that died, 1 transplanted in CR2 died of relapse, while another transplanted in CR2 died of ARDS. Both were recipients of related donor grafts. These data demonstrate hematopoietic stem cell transplantation is a viable therapeutic option for pediatric patients with isolated CNS relapse, and suggests that a larger multi-institutional analysis should be undertaken.

Sign in / Sign up

Export Citation Format

Share Document